Strides Pharma receives USFDA nod for its greenfield oral facility in Singapore

Pharmaceutical major Strides Pharma Science Ltd said it received approval from the United States  Food and Administration for its greenfield oral medication facility in Singapore, giving a boost to the company’s efforts to bid for US government contracts.

The new unit will help the company supply its products to US government agencies as Singapore is covered by the Trade Agreement Act (TAA).

Under the TAA, certain products that are sold to the U.S. Government must originate either in the United States or in one of the countries with which the US  has a special trade agreement.

“The new facility will complement Strides’ existing manufacturing base and will help meet increased demand from its businesses across UK, Australia, US and Europe”, the company said.

The facility will produce over 1.4 billion capsules and tablets.

The plant has fully integrated manufacturing and packaging lines and has been built with emphasis on automation in both production and quality control laboratories.

It has been already  approved by the Health Science Authority (HSA), Singapore and Therapeutic Goods Administration (TGA), Australia.

Headquartered in Bengaluru, Strides  has a global manufacturing footprint with seven manufacturing facilities spread across three continents.

Apart from its two manufacturing facilities in Bengaluru, Strides also has manufacturing sites in Pondicherry, Chennai, Milan and Singapore.